Ropharma Bras risk profile
28 Normal where most of the sector sits
Measured 21 October 2026 from RPH's filed statements. Recomputed nightly.
28 (Normal), driven by Cash conversion at 49, over 5 weighted categories on the RETAILER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 34 | Normal | Stable | Average daily turnover — $4.1K |
| Operating pressure | 39 | Normal | Stable | Costs outgrowing revenue — -0.6 percentage points |
| Cash conversion | 49 | Elevated | Worsening | Capital spending against operating cash — 0.43x |
| Leverage and coverage | 40 | Elevated | Easing | Net debt to EBITDA — 2.54x |
| Competitive position | 7 | Contained | Stable | Revenue-growth gap against peers — +43.0 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.